Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center talks Diagnostic Criteria for Thrombotic Thrombocytopenic Purpura One needs less than…
Browsing: Acute Lymphoblastic Leukemia
Dr. Ann Eapen Division of Hematology/Oncology: UC Irvine discusses Positive Data for RR-CLL Patients Able to see MRD Negativity at…
Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center talks Highlights from MDS and Nonmalignant Hematology New drugs for MDS:…
Dr. Ann Eapen Division of Hematology/Oncology: UC Irvine discusses The CLARITY Trial Lead by Dr. Hillmen Feasibility study that looked…
Angela Fleischman MD PhD UC Irvine discusses JAK Inhibitors are a Central Theme in MPN Lots of JAK Inhibitors being…
Elizabeth Brém, MD – HS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses Rituximab Maintenance for Follicular Lymphoma CAR-T Trial…
Angela Fleischman MD PhD UC Irvine discusses Disease Managing Clonal Hematopoiesis of Indeterminate Potential (CHIP) Mutations associated with Myeloid Malignancies;…
Elizabeth Brém, MD – HS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses Echelon-1 Data Showed Modified Progression Free Survival…
Angela Fleischman MD PhD UC Irvine discusses Distinguishing Between Clonal Disorder & a Germ-Line Mutation Clonal disorder is a hematologic…
Elizabeth Brém, MD – HS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses Efficacy & Toxicity of CAR-T Trials and…
Angela Fleischman MD PhD UC Irvine discusses Preventing Progress of MPN Presently this area is limited and needs to be…
Elizabeth Brém, MD – HS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses updates on PRIMA Study Progression Free Survival…
Angela Fleischman MD PhD UC Irvine discusses MPN (Myeloproliferative Neoplasm) & CHIP New phenomenon in aging individuals with mutations associated…
Elizabeth Brém, MD – HS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses how CAR-T Therapies will Dominate in 2018…
Angela Fleischman MD PhD UC Irvine discusses Disease Modifying Agents on the Horizon for MPN Hope to impact, intervene, &…
Elizabeth Brém, MD – HS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses updates Retrospective Analysis Looked At Rituximab Maintenance…
Tyrosine kinase inhibitors (TKIs) are orally active, small molecules that exhibit antitumor activity by targeting enzymes that play a critical…
Tyrosine kinase inhibitors (TKIs) are orally active, small molecules that exhibit antitumor activity by targeting enzymes that play a critical…
Tyrosine kinase inhibitors (TKIs) are orally active, small molecules that exhibit antitumor activity by targeting enzymes that play a critical…
In this Velocity Vlog activity, Dr. Richard S. Finn of the UCLA Geffen School of Medicine, provides a brief overview…
Filanesib is a novel agent that has previously shown clinical activity in pretreated multiple myeloma (MM) patients. In this interview,…
Enrique Ocio, MD, PhD, from University Hospital of Salamanca, Salamanca, Spain, gives us an overview of the GEM-Pembresid trial (NCT02636010),…
VCD (bortezomib, cyclophosphamide and dexamethasone) is an effective chemotherapy combination commonly used for the treatment of newly diagnosed multiple myeloma…
The results of the Phase III MURANO trial (NCT02005471) were important to address a number of unanswered questions surrounding the…
Now that hematological oncologists have an arsenal of novel single agents, the natural next step is to determine the best…
With the increasing use of immunotherapy, methods of response testing need to be rigorous and comparable. However, as explained here…
There are many areas of uncertainty surround immunotherapy, which require further exploration in the coming years. Speaking from the British…
Now that there is a range of immunotherapies available, the next frontier to explore is immunotherapy combination regimens. In this…
At the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, Fred Hirsch, MD, PhD, of University…
Tumor mutational burden (TMB) is emerging as a promising predictive biomarker for lung cancer immunotherapy response. Here, Fred Hirsch, MD,…
With the great promise that immunotherapy holds, there are hopes that it will revolutionize the treatment of lung cancer. Here,…
With exciting data for immuno-oncology in lung cancer, there is much anticipation for what 2018 holds. In this interview, Solange…
Immunotherapy is an exciting area for lung cancer, with numerous possibilities and game-changing potential. Speaking from the British Thoracic Oncology…
After many negative trial results for non-small cell lung cancer (NSCLC) therapies for some time, the field is now evolving…
Numerous trials worldwide are now focusing on combination therapy for relapsed/refractory chronic lymphocytic leukemia (CLL). In this interview, Barbara Eichhorst,…
Data from the Phase III MURANO study (NCT02005471) is a hot topic in the field of hematological oncology. The study…
Sequential triple-T therapy is a regimen consisting of tailored and targeted treatment aiming for total eradication of minimal residual disease…
Fludarabine, cyclophosphamide and rituximab (FCR) is the standard chemotherapy regimen used to treat chronic lymphocytic leukaemia (CLL). In this interview,…
Over the past 10 years, there has been a massive expansion in the number and classes of treatments available for…
The last 5-10 years has been a very exciting time for the treatment of myeloid malignancies, with great advances in…
Presented by Robert Z. Orlowski, MD, PhD; and Peter M. Voorhees, MD. Part 1 of 3 of a symposium recorded…
Presented by Ajay K. Nooka, MD, MPH, FACP. Part 2 of 3 of a symposium recorded at an oncology specialty…
Presented by Ajay K. Nooka, MD, MPH, FACP; Robert Z. Orlowski, MD, PhD; and Peter M. Voorhees, MD. Part 3…
Data for non-chemotherapy-based treatments is increasing exponentially, with the presentations at the American Society of Hematology (ASH) 2017 Annual Meeting…
Immune checkpoint inhibitors and T-cell engaging bi-specific antibodies have shown promising activity against lymphoid malignancies. In this interview, Anthony Mato,…
Data from recent studies indicate that PD-1 and PD-L1/PD-L2 mediate immune evasion in chronic lymphocytic leukemia (CLL), highlighting their importance…
Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center talks about updates on Myelodysplastic syndrome and nonmalignant hemetology at MOASCs…
Angela Fleischman, MD, from UC Irvine joins us at MOASCs Spotlight On Hematology in Huntington Beach to discusses the updates…
Deepa Jeyakumar, MD, from UC Irvine Health discusses the Acute myeloid leukemia highlights from ASH 2017 at MOASCs Spotlight On®…
Elizabeth Brém, MD, from The Chao Comprehensive Cancer Center joins us at MOASCs Spotlight On® Hematology in Huntington Beach to…